Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire - Thu Dec 18, 6:05AM CST

ROCKVILLE, Md. , Dec. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44 th Annual J.P. Morgan Healthcare Conference.

RGNX : 13.51 (+2.58%)
REGENXBIO to Participate in Upcoming Investor Conference PR Newswire - Tue Nov 25, 6:05AM CST

ROCKVILLE, Md. , Nov. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conference:

RGNX : 13.51 (+2.58%)
Regenxbio: Q3 Earnings Snapshot AP - Thu Nov 6, 6:25AM CST

Regenxbio: Q3 Earnings Snapshot

RGNX : 13.51 (+2.58%)
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights PR Newswire - Thu Nov 6, 6:05AM CST

ROCKVILLE, Md. , Nov. 6, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the third quarter ended September 30, 2025.

RGNX : 13.51 (+2.58%)
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program PR Newswire - Thu Oct 30, 6:05AM CDT

ROCKVILLE, Md. , Oct. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the completion of enrollment in the AFFINITY DUCHENNE ® pivotal trial of RGX-202, an investigational...

RGNX : 13.51 (+2.58%)
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights PR Newswire - Wed Oct 29, 6:05AM CDT

ROCKVILLE, Md. , Oct. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 6, at 8:00 a.m. ET to discuss its financial...

RGNX : 13.51 (+2.58%)
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire - Wed Oct 15, 6:05AM CDT

ROCKVILLE, Md. , Oct. 15, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

RGNX : 13.51 (+2.58%)
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting PR Newswire - Thu Oct 9, 6:05AM CDT

ROCKVILLE, Md. , Oct. 9, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present interim data from the Phase II ALTITUDE ® trial evaluating suprachoroidal delivery...

RGNX : 13.51 (+2.58%)
Analysts Offer Insights on Healthcare Companies: Anavex Life Sciences (AVXL), RegenXBio (RGNX) and Vera Therapeutics (VERA) Tipranks - Wed Oct 8, 5:36AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Anavex Life Sciences (AVXL – Research Report), RegenXBio (RGNX – Research Report) and Vera Therapeutics...

VERA : 47.69 (-1.73%)
AVXL : 3.89 (-0.77%)
RGNX : 13.51 (+2.58%)
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD PR Newswire - Mon Oct 6, 6:05AM CDT

ROCKVILLE, Md. , Oct. 6, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the completion of enrollment in the ATMOSPHERE ® and ASCENT ® pivotal studies evaluating surabgene...

RGNX : 13.51 (+2.58%)

Barchart Exclusives

Mizuho Says This 1 Agentic AI Company Is the Top Software Stock to Buy in 2026 Barchart - Thu Dec 18, 9:47PM CST
Despite a rocky year for Salesforce shares, Mizuho remains bullish on the stock, naming it a top software pick for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot